US-based Ingenia plans $42M Kosdaq IPO for TIE2 pipeline
· marian chu
-ticker.webp?t=1785777974)
AI Briefing
- • US-based Ingenia Therapeutics plans $42M Kosdaq IPO to fund antibody pipeline.
- • IPO proceeds to be used for TIE2/VEGF bispecific compound licensed by Merck Sharp & Dohme.
- • Ingenia priced 5 million shares at $8.40 (₩12,000) per share on July 28.
Source Summary
Ingenia Therapeutics Co. Ltd. is seeking a $42 million IPO on the Korea Exchange this month, with proceeds to fund an antibody pipeline that includes a TIE2/VEGF bispecific compound licensed by Merck Sharp & Dohme LLC. Watertown, Mass.-based Ingenia solidified the plans for its Kosdaq debut by pricing 5 million shares at about $8.40 (₩12,000) per share on July 28.
Advertisement